GeoVax Labs will appeal its Nasdaq delisting determination at a hearing on October 13, 2026, while its common stock is expected to keep trading on the Nasdaq Capital Market through the hearing and any extension period. The company plans to present measures for regaining and maintaining compliance with Nasdaq listing standards.

Key Highlights

  • The Nasdaq Hearings Panel has scheduled GeoVax’s appeal for October 13, 2026.
  • GeoVax plans to present a compliance strategy addressing the applicable Nasdaq listing standards.
  • GEO-MVA remains the company’s priority program, with plans for a key Phase 3 clinical trial.

GeoVax Labs, Inc. (NASDAQ: GOVX) will appeal its Nasdaq delisting determination at a Hearings Panel session scheduled for October 13, 2026.

Nasdaq Appeal Sets October 13 Hearing

The delisting determination relates to Nasdaq Listing Rule 5550(a)(2) and its minimum bid price requirement. The company intends to present a plan for regaining and maintaining compliance with Nasdaq listing standards. Chairman and Chief Executive Officer David Dodd said the Nasdaq process does not change GeoVax’s strategic priorities or focus on execution. Chief Financial Officer Mark W. Reynolds signed the filing on September 10, 2026.

GEO-MVA Remains Priority Program

GeoVax is advancing GEO-MVA, an investigational Modified Vaccinia Ankara Vaccine targeting mpox and smallpox, under an expedited regulatory pathway.